Forum: Crucell » About Wyeth

gideon1404 8 jan 2009 om 00:26

0

About Wyeth

Wyeth is a global leader in pharmaceuticals, consumer health care products, and animal health care products.
Outstanding Global Brands, Exciting New Products and a Rich Research Pipeline
Wyeth improves the lives of millions of people around the world with its outstanding products. And new, innovative medicines are on the way. With research and development (R&D) programs focused on small molecules, vaccines, and biotechnology, Wyeth is exploring more than 90 new therapies for medical conditions such as diabetes, breast cancer, multiple sclerosis, Alzheimer’s disease, and schizophrenia.

Wyeth Pharmaceuticals
Wyeth has a long history of pioneering developments in pharmaceuticals and biotechnology, with leading products in the areas of women’s health care, neuroscience, musculoskeletal disorders, vaccines and infectious disease, hemophilia, and oncology. Wyeth also is a leader in the development of nutritionals.

Women’s Health Care
For more than 65 years, Wyeth has been a leader in women’s health care with its postmenopausal hormone therapies and oral contraceptives. Wyeth continues to have active product development programs in this important category and is committed to developing new therapies with the potential to significantly improve the health of women worldwide.

Neuroscience
Wyeth’s global neuroscience efforts have produced a novel therapy for depression and for the treatment of generalized anxiety disorder. Working with three discovery platforms—small molecules, vaccines and biotechnology—Wyeth researchers continue to develop treatments targeted for a wide range of central nervous system disabilities, such as multiple sclerosis, Alzheimer’s disease, depression, anxiety and schizophrenia.

Vaccines and Infectious Disease
Wyeth’s vaccines and infectious disease franchises share a common mission: to reduce the number of serious illnesses and deaths from bacterial and viral infections and to address the growing problem of bacterial resistance to existing treatments. In recent years, Wyeth has developed some of the most innovative vaccines in the health care arena. Our R&D focuses on producing vaccines for infants, children, and adults around the world. We are proud of the impact Wyeth has had on children’s lives, and we are dedicated to continually developing vaccines so children and adults can have a healthier future.

Musculoskeletal Disorders
Wyeth’s musculoskeletal disorders franchise develops important new therapies for patients with joint and bone disease. Our products include treatments for rheumatoid arthritis that help patients lead more active lives. In addition, Wyeth has a strong presence in the osteoarthritis treatment market. In research, Wyeth scientists are investigating novel treatments for bone and tissue repair.

Internal Medicine
Our internal medicine franchise includes gastrointestinal products. Wyeth’s internal medicine researchers are exploring novel approaches to treat diabetes and gastrointestinal disorders.

Hemophilia Treatment
Since the 1980s, Wyeth has been a global leader in the search for safer and more effective treatments for hemophilia A and B. As a result of this commitment and a significant investment in recombinant DNA technology, our efforts have led to important medical advances in the treatment of these potentially debilitating diseases.

Oncology
Our efforts in oncology include chemotherapy agents for acute myeloid leukemia, renal cell cancer, and a platelet growth promoter to help patients after chemotherapy. Wyeth currently has several promising oncology therapies in clinical trials, including treatments for non-Hodgkin's lymphoma, breast cancer, and chronic myeloid leukemia.

Wyeth Consumer Healthcare
Wyeth Consumer Healthcare is built on strong global brands, including some of the world’s most popular and best-known consumer health care products. Three of our well-established product lines—Advil®, Centrum®, and Robitussin®—are among the top nonprescription medicines in the world. Other key brands include ChapStick®, the Caltrate® family of calcium supplements, Alavert®, Preparation H®, and Dimetapp®.

Fort Dodge Animal Health
As a world leader in animal health, Fort Dodge Animal Health offers a broad range of biological and pharmaceutical products for the companion animal, equine, livestock, swine and poultry industries. Innovative Fort Dodge products include West Nile-Innovator®, Duramune® Adult,
CYDECTIN® Pour-on, the Pyramid® vaccine line, Quest® Gel and EtoGesic® Tablets.

Price & Volume
Recent Price 38.56
Trade Date 01/06/09
52 Week High 49.80
52 Week Low 28.06
52 Week Price Percent Change -18.77%
YTD Price Percent Change 2.80%
Volume (10 Day Average) (000) 4,852.60
Beta (5-Year) .63

Share Related
Market Cap (Total, All Common Classes) (mil) 51,116
Shares Outstanding (Total, All Classes) (mil) 1,331.49
Shares Outstanding Average, latest FYE (mil) 1,374.34

Data Provided by Thomson Financial

www.wyeth.com/healthcareprofessional

gocrucellgo 14 aug 2009 om 09:14

0

FDA needs more time to review proposed Prevnar 13 vaccine data
by Susan Todd/The Star-Ledger
Wednesday August 12, 2009, 9:15 AM
Federal drug regulators said yesterday they will need more time to review technical data about the proposed Prevnar 13 vaccine before it can be approved.

The Food and Drug Administration was originally scheduled to make a decision on Prevnar 13 at the end of September.

Now, a decision isn't expected until the end of December.

Regulators want to take a closer look at data validating the tools Wyeth uses to analyze the properties of the complex vaccine. The technical data has nothing to do with the safety of the product or Wyeth's manufacturing capabilities, the company said.

Prevnar 13 builds on the earlier version of the vaccine, adding protection against six more separate serotypes of the streptococcus pneumoniae, which is responsible for everything from ear infections to meningitis.

Wyeth said it provided the FDA with the information last month, and the agency subsequently decided it needed more time to carry out its review of the product.

The potential of Prevnar 13 -- global sales of Prevnar 7 soared to $2.7 billion last year -- was one of the reasons Pfizer pursued its acquisition of Madison-based Wyeth. The two drug makers are scheduled to complete their merger later this year.

www.nj.com/business/index.ssf/2009/08...

gocrucellgo 25 sep 2009 om 18:16

2

Wyeth says committee recommends Prevenar-13 OK

The Associated Press
NEW YORK -- Wyeth says European Union regulators are recommending approval for a new version of its children's pneumococcal vaccine, Prevenar 13.

The Madison, N.J., company says the Committee for Medicinal Products for Human Use recommended approval in children 6 weeks to 5 years to prevent pneumococcal disease, as well as pneumonia and middle ear infections caused by related viruses.

A final decision from the European Medicines Agency is expected in the coming months, the company says.

Wyeth, which is being bought by Pfizer for $68 billion, is seeking U.S. approval for the drug under the name Prevnar-13. The FDA is expected to make a ruling by Dec. 30.

The original Prevnar is Wyeth's second best-selling drug, with $2.7 billion in revenue in 2008.

www.miamiherald.com/business/nation/s...

ron banged 25 sep 2009 om 18:39

1

What the hell is the product submitted to the EMEA...and is Crucell involved with Prevnar 13?

From the transcript of Brus from UBS

Today, in
that platform, we have around 80 -- 8-0 -- partners, and none of them has reached
the market yet, but they're all royalty-bearing once they reach the markets. And
the first submission for a product that's being produce on the platform that we
offer has been submitted now to the EMEA, and we have reasonable hopes that
that will make it through. However, for us, it's a numbers game.

gocrucellgo 25 sep 2009 om 19:26

0

Originele bericht

09 / 25 / 2009

Wyeth Receives Positive Opinion from European Regulators for its 13-valent Pneumococcal Candidate Vaccine for Infants and Young Children
Collegeville, Pa., September 25, 2009 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company’s pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6 weeks to 5 years for the prevention of invasive pneumococcal disease, as well as pneumonia and otitis media (middle ear infection) caused by 13 pneumococcal serotypes. The CHMP’s opinion for Prevenar 13 will now be forwarded to the European Commission and a final decision is expected in the coming months.

“The CHMP’s positive opinion brings us one step closer to providing infants and young children in Europe with the broadest serotype coverage of any pneumococcal conjugate vaccine,” says Emilio Emini, Ph.D., Executive Vice President, Vaccine Research and Development, Wyeth Pharmaceuticals. “Prevenar, our currently available vaccine, has both proven clinical efficacy and documented effectiveness, which has resulted in a significant public health benefit. Prevenar 13 builds on the scientific foundation of Prevenar and, if approved, will provide coverage for the 13 most prevalent pneumococcal-disease causing serotypes, including serotype 19A, which has emerged as a serious public health threat in Europe and around the world.”

Prevenar 13* is designed to provide the broadest serotype coverage of any pneumococcal conjugate vaccine. The vaccine contains the seven serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) included in Prevenar* (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed) – the global standard in pneumococcal disease prevention in infants and young children – plus six additional serotypes (1, 3, 5, 6A, 7F and 19A) responsible for the greatest remaining burden of invasive disease. Both Prevenar and Prevenar 13 use CRM197 – an immunological carrier protein with a 20-year history of use in pediatric vaccines. Available in Europe since 2001, Prevenar is currently available in 97 countries and more than 265 million doses have been distributed worldwide.

To date, the company has submitted pediatric regulatory applications for Prevenar 13 in more than 50 countries spanning six continents. Prevenar 13 has been approved in two countries, with Chile being the first in July 2009. Prevenar 13 is also being studied in global Phase 3 clinical trials in adults, with regulatory submissions expected in 2010.
www.wyeth.com/news?nav=display&navTo=...

maxen 25 sep 2009 om 21:08

1

quote:
ron banged schreef:

What the hell is the product submitted to the EMEA...and is Crucell involved with Prevnar 13?

From the transcript of Brus from UBS

Today, in
that platform, we have around 80 -- 8-0 -- partners, and none of them has reached
the market yet, but they're all royalty-bearing once they reach the markets. And
the first submission for a product that's being produce on the platform that we
offer has been submitted now to the EMEA, and we have reasonable hopes that
that will make it through. However, for us, it's a numbers game.
[/quote]
Sigh...The 80 partners stuff is all about Per.C6 and STAR licensees. The contract with Wyeth is all about development and production of part of a Wyeth vaccine in the Swiss Berna facilities, and quite likely has nothing to do with the above, since likely Per.C6 is not necessarily involved (see PR below).

But are these activities at Berna for Prevnar-13 or for another future vaccine? I don't know for sure, but look at the timeline:

[quote=Crucell]
Leiden, The Netherlands, 3 March 2008 - Dutch biotechnology company Crucell N.V. today announced that it has entered into an exclusive vaccine development agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

Under the terms of the agreement, Crucell will be responsible for the development and manufacture of certain components of a vaccine for use by Wyeth in clinical studies. The development activities will take place in Crucell's dedicated vaccine manufacturing facilities in Bern, Switzerland. Wyeth will be responsible for the clinical development of the vaccine. Financial details were not disclosed.

en.wikipedia.org/wiki/Pneumococcal_co...
"In 2009, Wyeth will be introducing Prevnar 13.."

So, in 2009, Prevnar-13 has finished all its phase I,II,III trials, and in most countries it is either approved or is in the process of being approved. With this the case, it seems impossible that 'certain components' of Prevnar still needed to be developed in march 2008, and then go through all trials, and then be approved in just about 1 year.

So, hence it follows that Crucell/Berna is NOT involved in Prevnar 13. But still, Crucell COULD be involved in Prevnar 22 or 31....

Bonus:
en.wikipedia.org/wiki/Pneumococcal_co...
Pneumococcal conjugate vaccine (PCV) is a vaccine used to protect infants and young children against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). There are currently two PCV vaccines available on the global market: Prevnar (called Prevenar in some countries) and Synflorix.
...Synflorix is produced by GlaxoSmithKline.

maxen 25 sep 2009 om 21:50

2

Also interesting for the speculation on what is Crucell doing for Wyeth is this preceding 2006 news:

investors.crucell.com/C/132631/PR/200...

quote:
Crucell schreef:

Crucell Reports First Orders For Contract Manufacturing Agreement with Wyeth Biotech

Leiden, The Netherlands, December 15, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has received its first orders for the CMO agreement with New Jersey-headquartered Wyeth Biotech. The CMO agreement for formulation and filing of a vaccine was finalized end 2005 and will have the first business impact for Crucell in 2007. The vaccine will be supplied from Crucell's Swiss subsidiary.
[/quote]

This news became much more specific in this version (emphasis mine):

www.outsourcing-pharma.com/Contract-M...

[quote=outsourcing-pharma]
Wyeth kicks off CMO agreement with Crucell
By Anna Lewcock, 20-Dec-2006

Related topics: Contract Manufacturing, Drug delivery, formulation, Fill & finish, packaging

Crucell yesterday announced it had received the first orders from US-headquartered Wyeth Biotech. The order represents the first move following the finalisation of the contract manufacturing agreement between the two companies at the end of 2005.

The agreement is for the formulation and filing of a MENINGITIS vaccine, but Crucell remained tight-lipped regarding the volume of this and any further orders. The vaccine will be supplied from Crucell's Swiss subsidiary, Berna Biotech, which the company acquired earlier this year. The CMO agreement is expected to have the first business impact for Crucell in 2007.

It is obviously interesting that Prevnar -7 and -13 ARE meningitis vaccines (I am not sure Wyeth makes any other).

So it is still possible that, via the first agreement, Crucell IS involved in CMO production of (part of) Prevnar 13, and via the second agreement, IS involved in the development of a next Prevnar version.

...

MeawandMoo1 25 sep 2009 om 23:10

0

quote:
maxen schreef:

It is obviously interesting that Prevnar -7 and -13 ARE meningitis vaccines (I am not sure Wyeth makes any other).

So it is still possible that, via the first agreement, Crucell IS involved in CMO production of (part of) Prevnar 13, and via the second agreement, IS involved in the development of a next Prevnar version.

...

Presentatie (prevnar-focus)
library.corporate-ir.net/library/78/7...

(R&D-focus)
www.wyeth.com/irj/servlet/prt/portal/...

maxen 26 sep 2009 om 00:35

0

Dank MeawandMoo,

quote:
MeawandMoo1 schreef:

(R&D-focus)
...
[/quote]
De vaccins uit de hier gepresenteerde Wyeth pipeline:
[quote=Wyeth]
Phase 0:
Staphylococcus aureus* Staphylococcus aureus
* New addition since October 16, 2008 update

Phase I:
MnB rLP2086 (IM) Meningococcal Serogroup B (Infant)

Phase II:
MnB rLP2086 (IM) Meningococcal Serogroup B (Adolescent)

Phase III:
13vPnC (IM) Invasive Pneumococcal Disease (Adult)

Submitted for Registration:
Prevnar 13 Invasive Pneumococcal Disease (Infant)
Prevenar® (Pneumococcal 7-valent Conjugate Invasive Pneumococcal Disease (Infant) (Japan)
Vaccine [Diphtheria CRM197 Protein]) (SC)

Denkend aan het nieuwste Berna mede-ontwikkel project, dan lijkt me de jongste vaccin-ontwikkeling, nu nog in phase 0, de grootste kanshebber: Eeen vaccin tegen MRSA, Methicillin-resistant Staphylococcus aureus, oftewel 'ziekenhuisbacterie'.

Het vaccin uit phase I en II is tegen meningococcen, en zou denk in niet meer kunnen voor het 2e Crucell/Wyeth project (immers, dat moest eerst nog ontwikkeld worden voordat het in de clinical trials kan), maar, omdat het tegen meningitis is, voldoet het wel aan de beschrijving voor Crucell/Wyeths 1e project, waarin Crucell CMO productie voor Wyeth levert tegen een anti-meningitis vaccin (zie artikeltje hierboven). Wellicht nu nog maar in kleine hoeveelheden, alleen voor clinical trials?

Enigszins relevante achtergrond: Crucell ontwikkelt in ieder geval al antibodies tegen resistente bacterien (die van phase 0), samen met Medimmune:

investors.crucell.com/C/132631/PR/200...
Crucell Secures € 2 Million Grant from Dutch Ministry of Economic Affairs to Discover Antibodies Against Antibiotic-resistant Bacterial Infections

investors.crucell.com/C/132631/PR/200...
Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection

Dirk R. Wijnen 26 sep 2009 om 09:19

0

quote:
maxen schreef:

Crucell Reports First Orders For Contract Manufacturing Agreement with Wyeth Biotech

Leiden, The Netherlands, December 15, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has received its first orders for the CMO agreement with New Jersey-headquartered Wyeth Biotech. The CMO agreement for formulation and filing of a vaccine was finalized end 2005 and will have the first business impact for Crucell in 2007. The vaccine will be supplied from Crucell's Swiss subsidiary.

Dank, Maxen en MeawandMoo1,

Goed speurderswerk weer.

Jammer alleen dat Crucell's "biggest deal ever" nog geen Euro heeft opgeleverd, ondanks de toezeggingen dat het al in 2007 impact zou hebben.

Dirk

flosz 26 sep 2009 om 11:27

2

Ter aanvulling.

Een paar overige draadjes: www.iex.nl/forum/topic.asp?forum=228&...
crucell.yourbb.nl/viewtopic.php?f=8&t...
www.depers.nl/debeurs/discussies/onde...
**********

IV, unclebake:
Crucell - Wyeth CMO deal
This may be a bit late, but I thought it might clear up some of the basic questions about the Wyeth CMO announcement. I emailed Crucell IR about the PR. Below are the relevant parts of my query and the response I received. If this info posted previously,I missed it, sorry for duplication. Happy & healthy Holidays to all. unclebake.

my e-mail:
The recent press release (December 15, 2006) announcing that Crucell
"...has received its first orders for the CMO agreement with New
Jersey-headquartered Wyeth Biotech. The CMO agreement for formulation and
filing of a vaccine was finalized end 2005 and ..." was a welcome surprise
to me. I did not recall that Crucell had an agreement with Wyeth for
contract manufacturing services. Wanting to learn more about this new
revenue source for the company I reviewed all the press releases available
on the company web site issued around and following year end 2005. I also
reviewed the company's SEC filings for the year end 2005 and subsequent
quarterly filings. However, I was not able to find any mention or
discussion relating to an agreement with Wyeth.
Perhaps I have overlooked or missed this information. Or perhaps the
company did not consider it a sufficiently material agreement to warrant
inclusion in a press release or its regulatory filings. In any event, I
would appreciate it if you would direct me to where I might find such
information.
Thank you for your assistance.

Company Reply:
"With respect to your question on previous publications on the agreement with Wyeth I can inform you that the contract was awarded to Berna Biotech in 2005, which by then was not yet part of the Crucell group of companies. I checked with our Swiss colleagues whether any release or announcement was published at the time, but there was not."
**********

Leiden, The Netherlands, July 30 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.

Crucell's AdVac® technology is a recombinant vector technology used to develop novel adenoviral-based products.

PER.C6® technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.
***********

Terminated:
Crucell sluit PER.C6® licentieovereenkomst met Wyeth Pharmaceuticals
Leiden, 25 augustus 2004 - Het Nederlandse biotechnologiebedrijf Crucell N.V. (Euronext, NASDAQ: CRXL) heeft vandaag bekend gemaakt dat zij een PER.C6® licentieovereenkomst heeft gesloten met Wyeth Pharmaceuticals. Volgens deze overeenkomst kan Wyeth de PER.C6® productietechnologie gebruiken voor preklinische ontwikkeling van zijn onderzoeks- en ontwikkelingsprogramma's.
Crucell ontvangt aanvangs- en jaarlijkse betalingen. Verdere financiële gegevens zijn niet bekend gemaakt.

Licenses with Edwards, Innogenetics, SRC, VPM, Centocor,. Wyeth, Pangenetics and JCR were terminated.
hugin.info/132631/R/1108240/200212.pdf

ronbanged2 12 jun 2010 om 00:27

0

Wyeth.

Was dit de grootste con's ooit?

"Grootste deal ooit"? Nog niemand ooit wist waar het over ging. Niemand wist iets over. Ever.

Behalve Ronald Brus.

Ronald Brus is de Gatekeeper. Hij beslist wie het waard is om de details van iedere deal te horen. Hij vertelde ons aan "Trust Me" op de Wyeth deal. Haar grote. Echt groot.

Woorden zijn gegooid als "meer dan een miljard euro"

Toch heb je niet gemerkt, dat als ze praten over Quinvaxem, praten ze over hoe het is gegund 910 miljoen euro in de contracten. Nou ja.

Van 2006 tot 2012.

Wat weten we over de J + J contract? Alleen wat Ronald Brus ons heeft verteld.

Hij beweert dat het waard is "meer dan een miljard euro".

Maar geeft ons geen details over hoe dat miljard euro zou kunnen worden bereikt.

Is het meer dan 10 jaar?

Is het alleen als alle 5 producten goedgekeurd te krijgen?

Aangezien Crucell's track record van de kansen van die <1%!

Zullen we ooit weten wat de Wyeth deal ooit over? Waarschijnlijk niet. Wij zijn niet waardig.

We waren ooit een van de details van de J + J deal weten? Alleen als een project krijgt op de markt ... en dan zullen we ontdekken dat Ronald werd met behulp van overdrijving.

Het zou de moeite waard geweest van een miljard euro als Crucell had ontdekt een monoklonaal antilichaam dat genezen;

kaalheid, erectiestoornissen, kanker, lelijkheid en obesitas

de tuinman 12 jun 2010 om 06:18

3

en frustraties, obsessies enz

maxen 12 jun 2010 om 10:13

3

quote:
ronbanged2 schreef:

...
Het zou de moeite waard geweest van een miljard euro als Crucell had ontdekt een monoklonaal antilichaam dat genezen;

kaalheid, erectiestoornissen, kanker, lelijkheid en obesitas

Wederom een bewijs dat je in het verkeerde bedrijf belegt.

De meeste investors verdiepen zich in een bedrijf voordat ze erin beleggen. Je hoeft niet erg diep te gaan om te vinden dat Crucell zich specialiseert in infectieziekten. Bij mijn weten vallen bovenstaande hier niet onder (paar uitzonderingen bij kanker).

Dus zoek gerust verder naar een bedrijf die wel dit soort 'aandoeningen' tracht te bestrijden, bijvoorbeeld een van die prachtige innovatieve, in de US uitgevonden telsell bedrijven.

(P.S. kaalheid? lelijkheid? obisitas? Tal van Brus-comments on weelderige haardos en gebruinde huid? Zien we hier weer een persoonslijke frustatie van een ouwe uitgezakte kaalkop met het jonge-god uiterlijk van Brus? Vreemd allemaal).

aossa 12 jun 2010 om 10:39

2

quote:
maxen schreef:

[quote=ronbanged2]
...
Het zou de moeite waard geweest van een miljard euro als Crucell had ontdekt een monoklonaal antilichaam dat genezen;

kaalheid, erectiestoornissen, kanker, lelijkheid en obesitas
[/quote]
Wederom een bewijs dat je in het verkeerde bedrijf belegt.

De meeste investors verdiepen zich in een bedrijf voordat ze erin beleggen. Je hoeft niet erg diep te gaan om te vinden dat Crucell zich specialiseert in infectieziekten. Bij mijn weten vallen bovenstaande hier niet onder (paar uitzonderingen bij kanker).

Dus zoek gerust verder naar een bedrijf die wel dit soort 'aandoeningen' tracht te bestrijden, bijvoorbeeld een van die prachtige innovatieve, in de US uitgevonden telsell bedrijven.

(P.S. kaalheid? lelijkheid? obisitas? Tal van Brus-comments on weelderige haardos en gebruinde huid? Zien we hier weer een persoonslijke frustatie van een ouwe uitgezakte kaalkop met het jonge-god uiterlijk van Brus? Vreemd allemaal).

De Diplom Kaufmann mist inderdaad enkele haren ter hoogte van het voorhoofd. Van biotech kent hij niets, medical devices, hospital catering en diagnostics is/was zijn ding... Met de verkoop van Rhein Biotech deed hij goede zaken, maar de verkoop van Berna aan Crusell ligt hem nog zwaar op de maag (Brus beloog hem, en zijn beleggingsvrienden, namelijk) en ze zitten samen nog steeds op dat pak omgeruilde aandelen. Maar waarom hij steeds de koers naar beneden praat weet ik niet... het is mogelijk frustratie!

aossa 12 jun 2010 om 11:20

0

Haha... zijn hoop is dat Crusell aandelen gaat inkopen!

/quote
"I've seen the conditions of the deal. It says J+J, one of the biggest companies in the world, owns 18%. Crucell can't buy back more than 1.2 million shares because that will put J+J over 20%" /

PS. Voorgaande is een 'robotfoto' opgemaakt uit de talrijke uitspraken en 'slips of the tongue'.

xynix 12 jun 2010 om 11:24

1

Ron: volgens mij kunnen de Nederlandse forumbezoekers gemakkelijker Engels lezen dan het vreemde Nederlands dat uit Google Translate komt lopen. De frequentie van jouw kritiekpostings zou wat mij betreft minder mogen. Maar met de strekking ben ik het vaak eens, zonder mijn ogen te sluiten voor de dingen die WEL goed gaan bij Crucell. Maar het zou met een competent en eerlijk MT VEEL beter kunnen gaan met dit bedrijf en zeker met de aandeelhouders.

[Modbreak IEX]: Deel van het bericht verwijderd.]

aossa 12 jun 2010 om 11:57

1

[Modbreak IEX]: Gelieve niet over elkaar te discussiëren, een aantal berichten is verwijderd.]

Hearts23 12 jun 2010 om 12:01

4

quote:
xynix schreef:

[Modbreak IEX]: Quote verwijderd.]

Wat dacht je : het is te rustig, ik graaf de strijdbijl maar weer eens op ? Bespaar ons dit aub.

harrysnel 15 jun 2010 om 22:53

3

Update Wyeth:

Goldman Sachs 31st Annual Global Healthcare Conference
www.pfizer.com/investors/presentation...
Webcast van Business Unit Speciality Care & Vaccines, gegeven door Geno Germano (ex-Wyeth).

Belangrijkste onderwerp is Prevnar13 en meer in het algemeen de strategie van business unit. Sterke punt is brede expertise over het gehele speelveld, de pipeline en het zijn van de "ideale partner" voor andere farma's.Ook aandacht integratie Pfizer/Wyeth.Vanaf 21:30 Capita trial in Nederland. Pneumococcal pneumonia als additionele indicatie; streven naar routine vaccinatie bij mensen boven 50. Prev. 13 geeft langere bescherming. Min 28: over meningitis, zit in Fase 2, afhankelijk van data extra fase 2 of door naar fase 3. Minder potentie dan Prevnar maar toch "substantial"..

Koers	0,000	Verschil	0,00 (0,00%)
Laag	0,000	Volume	0
Hoog	0,000	Gem. Volume	0
01-jan-01 00:00

21 mei	Taktisch: Capped Bonus Cert. op Dow
21 mei	'Tegenwind gaat eindelijk liggen'
21 mei	UBS: 5 verdachten voor een zeepbel
21 mei	Dr. Copper, topper of flopper?
21 mei	Must Read: Hedgen met obligaties

20 mei	ING Equity Research herhaalt het koopadvies voo...
20 mei	Goldman Sachs herhaalt het koopadvies voor SBM ...
20 mei	Citigroup Smith Barney verlaagt het koopadvies ...
20 mei	JPMorgan Cazenove verlaagt het koopadvies voor ...
17 mei	ABN AMRO verlaagt het koopadvies voor Coca-Cola...

1	ednique	+56,47%
2	roden050	+49,74%
3	SuperBoeg	+41,20%
4	battal	+40,73%
5	geenantwoord	+39,16%

Crucell « Terug naar discussie overzicht

About Wyeth

Plaats een reactie

Meedoen aan de discussie?

Direct naar Forum

Meer »

Gerelateerde Video's Meer »

Mijn watchlist Meer »

Mijn portefeuilles Meer »

Mijn forums Meer »

Het IEX Netwerk

Opinie

Actueel

Koersen

Forum

Wiki

Secties

Mijn IEX

Over IEX

E-mailadres:
Wachtwoord:
	Onthouden